RIPK1

Across TCGA pan-cancer cohorts, RIPK1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RIPK1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RIPK1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RIPK1 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

HNSC, COAD, and CCRCC are the cancer types where RIPK1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RIPK1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.198	<.001	11	view →
COAD	Male	II,III,IV	−0.127	<.001	10	view →
CCRCC	Male	II,III,IV	+0.167	<.001	7	view →
LUAD	Male	All	+0.155	<.001	7	view →
LSCC	All	All	+0.052	.020	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RIPK1–HNSC

Open the HNSC breakdown →